Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288559 · ClinicalTrials.gov registry record · Phase 2
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
A Phase 2 study of Geographic Atrophy, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT02288559 is a Phase 2 study of Geographic Atrophy that has completed, run by Genentech. The registered enrollment target is 96 participants, below the 218-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02288559, a Phase 2 study of Geographic Atrophy, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). A safety run-in assessment will be conducted prior to initiating enrollment in the randomized study.
Conditions Studied
Interventions
- OTHER Sham
- DRUG Lampalizumab
Study Locations (20)
California
- Retinal Diagnostic Center - Campbell
- The Retina Partners - Encino
- Loma Linda University - Loma Linda
- San Diego Retina Associates - Oceanside
- West Coast Retina Medical Group - San Francisco
- California Retina Consultants - Santa Barbara
Florida
- Florida Eye Microsurgical Inst - Boynton Beach
- National Ophthalmic Research Institute - Fort Myers
- Florida Eye Associates - Melbourne
- Retina Care Specialists - Palm Beach Gardens
- Retina Specialty Institute - Pensacola
Arizona
- Barnet Dulaney Perkins Eye Center - Mesa
- University of Arizona; Banner University Medical, Department of Opthalmology - Tucson
Arkansas
- Northwest Arkansas Retina Associates - Springdale
Colorado
- Colorado Retina Associates, PC - Golden
Illinois
- Rush University Medical Center - Chicago
Iowa
- Wolfe Eye Clinic - West Des Moines
Maryland
- Elman Retina Group - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2015-03-30 |
| Est. Completion | 2017-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02288559
The ClinicalTrials.gov registry entry for NCT02288559 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (56% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT02288559 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02288559 about?
NCT02288559 is a clinical study titled "A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy". This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in participants with geographic atrophy (GA) secondary to age-related mac...
What is the current status of trial NCT02288559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2015-03-30. Estimated completion is 2017-06-02.
What conditions does trial NCT02288559 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT02288559?
The interventions under investigation include: Sham (OTHER), Lampalizumab (DRUG).
Who is sponsoring clinical trial NCT02288559?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02288559 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RECRUITING · Phase 2
-
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.